<DOC>
	<DOCNO>NCT01401933</DOCNO>
	<brief_summary>This phase 1 , open-label study design determine interaction rifampin linifanib .</brief_summary>
	<brief_title>Effect Rifampin Pharmacokinetics Linifanib Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>This study design explore drug interaction rifampin linifanib determine potential effect rifampin metabolism linifanib . Linifanib take alone combination rifampin . The safety single dose administration linifanib administer alone combination rifampin assess . Subjects may enroll separate extension study continue receive linifanib completion study .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusion Criteria 1 . Age great equal 18 year . 2 . Subject must histologically cytologically confirm nonhematologic malignancy HCC . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . 4 . Subject must adequate bone marrow , renal hepatic function . Bone Marrow : Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 ( 1.5 X 10^9/L ) ; Platelets &gt; = 75,000/mm^3 ( 75 X 10^9/L ) ; Hemoglobin &gt; = 9.0 g/dL ( 1.4 mmol/L ) Renal function : serum creatinine &lt; = 2.0 mg/dL ( 0.81 mmol/L ) ; Hepatic function : AST ALT &lt; = 1.5 X ULN unless liver metastasis present , AST ALT &lt; = 5.0 X ULN ; bilirubin &lt; = 1.5 mg/dL ( 0.026 mmol/L ) . 5 . Subject must Partial Thromboplastin Time ( PTT ) &lt; /= 1.5 X Upper Limit Normal ( ULN ) International Normalized Ratio ( INR ) &lt; /= 1.5 . Exclusion Criteria 1 . Subject receive anticancer therapy include investigational agent , cytotoxic chemotherapy , radiation therapy biologic therapy within 21 day within period define 5 half life , whichever short , prior study drug administration . In addition subject recover less equal Grade 1 clinically significant adverse effects/toxicities previous therapy . 2 . Subject undergone major surgery within 21 day Study Day 1 . 3 . Subject untreated brain meningeal metastasis . Subjects treat brain metastasis radiographically clinically stable ( least 4 week therapy ) evidence cavitation hemorrhage brain lesion , eligible provide asymptomatic require corticosteroid ( must discontinue steroid least 1 week prior Study Day 1 ) . 4 . Subject receive potential inhibitor metabolism linifanib within 21 day prior initial study drug administration . Such drug include CYP3A inhibitor , CYP1A2 inhibitor , CYP2C19 inhibitor , CYP2C8 substrates CYP3A inducer . 5 . Current enrollment another clinical trial..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>